SERATRODAST

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H26O4
Molecular Weight	354.4394
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O

InChI

InChIKey=ZBVKEHDGYSLCCC-UHFFFAOYSA-N

InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)

HIDE SMILES / InChI

Molecular Formula	C22H26O4
Molecular Weight	354.4394
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.wikidoc.org/index.php/Seratrodast
Curator's Comment: Description was created based on several sources, including: http://www.tabletwise.com/seradair-tablet https://www.1mg.com/drugs/seretra-80-mg-tablet-130697

Seratrodast belongs to a class of medication called thromboxane A2/prostaglandin endoperoxide receptor antagonist. Seratrodast blocks the broncho-constrictor effects of certain chemicals (prostaglandins) in the body. Seratrodast also decreases the inflammation by antagonising the thromboxane A2 receptor. Adverse effects include gastrointestinal disturbances, drowsiness, headache, palpitations, and hepatitis. Seradair may interact with Ozagrel.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thromboxane A2 receptor 20 Target ID: CHEMBL2069 Sources: https://seratrodast.wordpress.com/molecular-modeling/	Antagonist 2849		60.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 244 Sources: http://www.kegg.jp/medicus-bin/japic_med?japic_code=00002634	Primary		Approved 8583	Bronica Approved Use Seratrodast is used for the prevention and treatment of mild to moderate asthma.

C_max

Value	Dose	Analyte	Population
8.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9357394/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SERATRODAST plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.88 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9357394/	120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SERATRODAST plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.4 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.4 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
13.8 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.6 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14.7 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
15.7 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
25.3 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
23.2 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
39.9 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
22.9 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg 1 times / day steady-state, oral dose: 320 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
37.4 μg/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg 1 times / day steady-state, oral dose: 320 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Analyte	Population
22.96 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9357394/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SERATRODAST plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
36.52 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9357394/	120 mg 1 times / day multiple, oral dose: 120 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SERATRODAST plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
192 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
197 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
302 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
271 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
350 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
166 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
231 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
334 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
435 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
351 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg 1 times / day steady-state, oral dose: 320 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
582 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg 1 times / day steady-state, oral dose: 320 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
18.5 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
19.7 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
26.2 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16.5 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
18 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg single, oral dose: 320 mg route of administration: Oral experiment type: SINGLE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
34.3 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
40.6 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
34.1 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
40.3 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	240 mg 1 times / day steady-state, oral dose: 240 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
42 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg 1 times / day steady-state, oral dose: 320 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27.9 h EXPERIMENT https://link.springer.com/article/10.2165/00044011-199714060-00008	320 mg 1 times / day steady-state, oral dose: 320 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SERATRODAST plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

Doses

Dose	Population	Adverse events
120 mg 1 times / day multiple, oral Highest studied dose Dose: 120 mg, 1 times / day Route: oral Route: multiple Dose: 120 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9357394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9357394/	Sources: https://pubmed.ncbi.nlm.nih.gov/9357394/
120 mg single, oral Highest studied dose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8162671/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/8162671/	Sources: https://pubmed.ncbi.nlm.nih.gov/8162671/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP19A1 429 CYP2E1 1060 CYP3A 227 CYP2A6 879 CYP1A2 2153 BSEP 550 CYP2C19 2057	CYP2B6 776 CYP2C8 810 CYP2C9/10 4 CYP2C19 1119 CYP1A2 1197 CYP2E1 729 CYP2A6 626

Drug as perpetrator

Target	Modality	Activity
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	no [IC50 >200 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/743139#sid=144206327	no
CYP3A 317	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	weak [IC50 180 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	weak [IC50 200 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	yes [IC50 50 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	yes [IC50 60 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	yes [IC50 95 uM]
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22961681/	yes [IC50 <14.31 uM]

Drug as victim

Target	Modality	Activity
CYP2C9/10 4	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	major
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	major
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	minor
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	minor
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	no
CYP2A6 626	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	no
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	no
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	no
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9010637/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/588834#sid=50125893

PubMed

Title	Date	PubMed
Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein.	2002-09	12153692
Mechanisms underlying cerebrovascular effects of cigarette smoking in rats in vivo.	1998-08	9707209

Patents

Sample Use Guides

In Vivo Use Guide

It is given in single doses of 80 mg in the evening after food.

Route of Administration: Oral

In Vitro Use Guide

Seratrodast competitively inhibited the contractile response to U-46619, PGD2, 9-alpha, 11beta-PGF2, or PGF2-alpha with pA2 values of 7.69, 7.20, 7.79, and 5.71, respectively.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:12:32 GMT 2025` Edited by `admin` on `Mon Mar 31 18:12:32 GMT 2025`
Record UNII	4U58JM421N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BRONICA

Preferred Name

English

SERATRODAST

Official Name

English

SERATRODAST [JAN]

Common Name

English

(±)-2,4,5-TRIMETHYL-3,6-DIOXO-.ZETA.-PHENYL-1,4-CYCLOHEXADIENE-1-HEPTANOIC ACID

Systematic Name

English

ABBOTT 73001

Code

English

Seratrodast [WHO-DD]

Common Name

English

AA-2414

Code

English

SERATRODAST [MI]

Common Name

English

seratrodast [INN]

Common Name

English

ABBOTT-73001

Code

English

ABT-001

Code

English

BENZENEHEPTANOIC ACID, .ZETA.-(2,4,5-TRIMETHYL-3,6-DIOXO-1,4-CYCLOHEXADIEN-1-YL)-, (±)-

Common Name

English

NSC-759640

Code

English

(±)-7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYLHEPTANOIC ACID

Systematic Name

English

SERATRODAST [USAN]

Common Name

English

SERATRODAST [MART.]

Common Name

English

A-73001

Code

English

Classification Tree Code System Code

WHO-ATC

R03DX06